pipette
ESEspañol

In-country cerebrospinal fluid metagenomic next generation sequencing for pathogen detection in Lima, Peru

S. P. Reddy, A. Chavez Neyra, K. Lugo, B. Ayzanoa, C. Cucho Espinoza, J. Morgenroth-Rebin, O. A. Bocanegra, D. Cuicapuza Arteaga, M. Saavedra, C. Gerungan, K. C. Zorn, F. C. Chow, F. Llanos Tejada, A. G. Lescano, P. Tsukayama, M. L. Santolalla, M. R. Wilson, R. Villanueva-Villegas

PreprintReal-world use

In the authors' words

Background: Central nervous system (CNS) infections are a major cause of morbidity and mortality in low- and middle-income countries such as Peru. However, their epidemiology is poorly characterized due to a wide range of endemic and opportunistic pathogens involved and limited access to specialized neurodiagnostic testing. Cerebrospinal fluid (CSF) metagenomic next-generation sequencing (mNGS) can detect any pathogen in a single hypothesis-free assay but has largely been confined to reference laboratories in high-income countries due to high cost and infrastructure requirements. We piloted an in-country, research-based CSF mNGS protocol in Lima, Peru, as a proof-of-concept study to assess the feasibility of implementing this approach in a resource-limited setting. Methods: Adults admitted with suspected CNS infection at Hospital Nacional Dos de Mayo, a large public hospital in Lima, were enrolled from August 2024 to April 2025, and approximately 0.5-2 mL of surplus CSF was collected. CSF mNGS (DNA and RNA) was performed in-country on a benchtop sequencer with half-volume library reactions and cloud-based analysis (CZID). Paired sequencing at a significantly higher depth was performed on a subset of samples in the United States for validation. Results: Among 43 participants (median age 48 years; 21% living with HIV), mNGS performed in Peru detected 20 pathogens in 18 samples (42%), of which 65% were not identified by routine clinical testing. Nine of 15 patients treated empirically for tuberculous meningitis were found to have a non-mycobacterial infection. Detected organisms included Toxoplasma gondii, Taenia solium, Treponema pallidum, human T-lymphotropic virus 1, herpesviruses, and, on deeper sequencing, Venezuelan equine encephalitis virus. Deep sequencing yielded 3.7-fold (DNA) and 6.9-fold (RNA) more reads and recovered four pathogens missed at shallower-depth. Conclusions: In-country CSF mNGS was feasible in Lima, Peru and recovered a clinically and epidemiologically meaningful spectrum of CNS pathogens, most missed by routine testing. By utilizing available, lower-output sequencers, we overcame a principal barrier to deploying this technology where the burden of undiagnosed CNS infection is greatest.

Main resultLimitation the authors admit

Appeared: Monday, November 16. medRxiv. Preprint, not yet peer-reviewed.

DOI: 10.64898/2026.11.13.26367457